相关临床试验
150
91 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
60
40.0%
已完成
19
12.7%
尚未招募
31
20.7%
招募中
34
22.7%
Unknown
4
2.7%
撤回
2
1.3%
暂无批准数据
- The landmark SNAP trial, involving 1,341 patients across eight countries, demonstrated cefazolin is at least as effective as flucloxacillin for MSSA bloodstream infections, with 90-day mortality of 15% versus 17%. - Cefazolin was associated with significantly fewer cases of acute kidney injury (14%) compared with flucloxacillin (20%), establishing a superior safety profile. - Researchers and clinicians now recommend cefazolin as the new first-line standard of care for most adults with methicillin-susceptible S. aureus bacteremia. - The findings, published in the New England Journal of Medicine, represent the largest randomized trial ever conducted for S. aureus bloodstream infections and challenge decades of clinical practice.
- Khondrion has dosed the first patient in its pivotal Phase 3 KHENERFIN study evaluating sonlicromanol for m.3243A>G-related primary mitochondrial disease, the most common genetic defect causing this rare condition. - The 52-week randomized trial will enroll up to 220 adult patients across Europe, the UK, and US, with primary endpoints focusing on chronic fatigue and muscle weakness reduction. - Sonlicromanol is a novel brain-penetrant redox-modulator with anti-ferroptotic and anti-inflammatory properties, representing a potential first treatment for this progressive and debilitating condition. - The company has also initiated a separate Phase 2 trial investigating sonlicromanol for post-COVID fatigue syndrome, expanding the drug's therapeutic potential beyond rare diseases.
- A multinational randomized clinical trial demonstrates that precision immunotherapy tailored to patients' immune profiles significantly improved organ dysfunction in sepsis patients. - The ImmunoSep study enrolled 276 patients across six countries, stratifying them based on immune status into macrophage activation-like syndrome or sepsis-induced immunoparalysis groups. - Patients receiving targeted immunotherapy showed 35.1% improvement in organ dysfunction compared to 17.9% in placebo group, though 28-day mortality rates remained unchanged. - The precision approach represents a critical advancement over previous "one-size-fits-all" immunotherapy strategies that have repeatedly failed in sepsis treatment.
